Vascular checkpoints for cancer immunotherapy

Cancer immunotherapy is based on the ability of immune cells, and in particular of T lymphocytes, to recognize neoantigens in tumor cells, and thus to cause their destruction. During their evolution, tumors develop multiple strategies that suppress T-cell based immune responses to evade their immunodestruction. One of these evasive mechanisms is based on the selective blockade of  the entry of effector T lymphocytes into the tumor microenvironment (TME), thus